Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track JSPR with free AI briefings, catalyst countdowns, and dilution alerts.

JSPR · Jasper Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$7.3M Cash on Hand
2mo Cash Runway
Follow JSPR by email Get an email when JSPR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about JSPR, unsubscribe in one click. Privacy

📣 What JSPR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Nelfinavir Healthy Volunteers Phase 4 · NCT00251030 Completed
Briquilimab (JSP191) Urticaria Chronic Phase 2 · NCT06736262 Terminated
Cycloserine Social Anxiety Disorder Early Phase 1 · NCT02066792 Completed

Also used in these trials (approved or third-party drugs, not JSPR's own candidates): Nicotine, Isradipine, Lomustine, Temozolomide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

JSPR holds $7.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $10.7M/quarter from operations, an estimated runway of 2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when JSPR files for a raise →

👥 Who Owns JSPR

Insiders 76.1% Other 5%+ holders 23.9% Institutions 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Velan Capital Investment Management LP 5%+ holder (13G) 3,363,347 303.24% 2026-08-17
BANK OF AMERICA CORP /DE/ Institution (13G, 5%+) 2,133,861 192.39% 2026-09-30
Affinity Asset Advisors, LLC Institution (13G, 5%+) 1,850,000 166.80% 2026-09-30
Anders Hove 5%+ holder (13G) 1,486,492 134.02% 2026-01-23
Patrick J Crutcher
Director · +23,388 options
Insider 518,331 46.73% 2026-07-16
Judith Anne Shizuru
Director · +56,000 options
Insider 156,901 14.15% 2025-09-22
Armistice Capital, LLC Institution (13G, 5%+) 123,102 11.10% 2026-09-30
Ron Martell
President, CEO and Director, Director · +649,000 options
Insider 74,118 6.68% 2025-09-22
Thomas G Wiggans
Director · +56,000 options
Insider 46,000 4.15% 2025-09-22
Jeetinder Singh Mahal
CEO and President, Director · +743,772 options
Insider 25,009 2.25% 2024-12-12
Svetlana Lucas
Director · +50,000 options
Insider 20,000 1.80% 2025-09-22
Wenru Song
EVP, Head of R&D
Insider 3,150 0.28% 2026-07-16

Share count 1,109,133 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full JSPR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JSPR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.